illumiSonics and Sunnybrook Launch INOVAIT Focus Fund–Backed Clinical Trial Bringing Label-Free Laser Histology to Mohs Skin Cancer Surgery
First prospective study to validate Multi-Laser Imaging (MLI™) virtual histology against the frozen-section gold standard in a live surgical setting
illumiSonics Inc., a medical technology company commercializing label-free tissue imaging, today announced the launch of a prospective clinical validation study at Sunnybrook Health Sciences Centre evaluating its Multi-Laser Imaging (MLI™) platform for skin cancer margin assessment during Mohs micrographic surgery. The study is led by Principal Investigators Dr. Deepak Dinakaran (radiation oncology) and Dr. Robert Bobotsis (dermatology).
The single-centre, prospective, observational study will enroll up to 200 patients undergoing Mohs surgery at Sunnybrook’s multidisciplinary dermatology clinic between July 2026 and December 2028. It is the first prospective clinical evaluation of MLI virtual histology, building on retrospective work in which the technique showed greater than 95% agreement with conventional histology for cancer type and 92% agreement for margin assessment, with pathologists unable to reliably distinguish MLI virtual slides from conventional chemically stained slides.
